Orally Inhaled Bronchodilators to 2022

Orally Inhaled Bronchodilators to 2022

  • April 2015 •
  • Report ID: 2841930
Asthma and COPD continue to be a health segments that present significant challenges to patients and the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they relax smooth muscles in the airways, bronchodilators are an indispensable tool for the treatment of upper respiratory diseases. The market entry of combination drug inhalers that deliver a bronchodilator and a corticosteroid from the same inhaler are providing important options for both clinicians and patients.

Highlights

• Analyzes the market for bronchodilator drugs delivered via oral inhalers
• Assesses inhalation device technology for delivering bronchodilators orally, and evaluates product technology issues and evolving market factors
• Provides detailed assessments of orally inhaled bronchodilator product segments, growth prospects and market potential
• Provides market data and forecasts for orally inhaled bronchodilators to 2022
• Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
• Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners